S&P 500   5,033.14 (-0.36%)
DOW   37,799.34 (+0.00%)
QQQ   427.50 (-0.84%)
AAPL   168.72 (-0.39%)
MSFT   412.76 (-0.44%)
META   495.86 (-0.78%)
GOOGL   156.01 (+1.04%)
AMZN   181.69 (-0.89%)
TSLA   157.60 (+0.31%)
NVDA   852.62 (-2.46%)
AMD   156.35 (-4.35%)
NIO   3.95 (+3.67%)
BABA   69.21 (-0.57%)
T   16.14 (+0.31%)
F   12.12 (+0.25%)
MU   117.49 (-3.51%)
GE   155.44 (-0.84%)
CGC   6.67 (-0.45%)
DIS   113.52 (-0.32%)
AMC   2.95 (+8.46%)
PFE   25.46 (-0.90%)
PYPL   63.37 (-0.09%)
XOM   118.64 (-0.04%)
S&P 500   5,033.14 (-0.36%)
DOW   37,799.34 (+0.00%)
QQQ   427.50 (-0.84%)
AAPL   168.72 (-0.39%)
MSFT   412.76 (-0.44%)
META   495.86 (-0.78%)
GOOGL   156.01 (+1.04%)
AMZN   181.69 (-0.89%)
TSLA   157.60 (+0.31%)
NVDA   852.62 (-2.46%)
AMD   156.35 (-4.35%)
NIO   3.95 (+3.67%)
BABA   69.21 (-0.57%)
T   16.14 (+0.31%)
F   12.12 (+0.25%)
MU   117.49 (-3.51%)
GE   155.44 (-0.84%)
CGC   6.67 (-0.45%)
DIS   113.52 (-0.32%)
AMC   2.95 (+8.46%)
PFE   25.46 (-0.90%)
PYPL   63.37 (-0.09%)
XOM   118.64 (-0.04%)
S&P 500   5,033.14 (-0.36%)
DOW   37,799.34 (+0.00%)
QQQ   427.50 (-0.84%)
AAPL   168.72 (-0.39%)
MSFT   412.76 (-0.44%)
META   495.86 (-0.78%)
GOOGL   156.01 (+1.04%)
AMZN   181.69 (-0.89%)
TSLA   157.60 (+0.31%)
NVDA   852.62 (-2.46%)
AMD   156.35 (-4.35%)
NIO   3.95 (+3.67%)
BABA   69.21 (-0.57%)
T   16.14 (+0.31%)
F   12.12 (+0.25%)
MU   117.49 (-3.51%)
GE   155.44 (-0.84%)
CGC   6.67 (-0.45%)
DIS   113.52 (-0.32%)
AMC   2.95 (+8.46%)
PFE   25.46 (-0.90%)
PYPL   63.37 (-0.09%)
XOM   118.64 (-0.04%)
S&P 500   5,033.14 (-0.36%)
DOW   37,799.34 (+0.00%)
QQQ   427.50 (-0.84%)
AAPL   168.72 (-0.39%)
MSFT   412.76 (-0.44%)
META   495.86 (-0.78%)
GOOGL   156.01 (+1.04%)
AMZN   181.69 (-0.89%)
TSLA   157.60 (+0.31%)
NVDA   852.62 (-2.46%)
AMD   156.35 (-4.35%)
NIO   3.95 (+3.67%)
BABA   69.21 (-0.57%)
T   16.14 (+0.31%)
F   12.12 (+0.25%)
MU   117.49 (-3.51%)
GE   155.44 (-0.84%)
CGC   6.67 (-0.45%)
DIS   113.52 (-0.32%)
AMC   2.95 (+8.46%)
PFE   25.46 (-0.90%)
PYPL   63.37 (-0.09%)
XOM   118.64 (-0.04%)
NASDAQ:ACST

Acasti Pharma (ACST) Stock Price, News & Analysis

$3.20
-0.15 (-4.48%)
(As of 01:04 PM ET)
Today's Range
$3.16
$3.31
50-Day Range
$2.36
$3.48
52-Week Range
$1.72
$3.84
Volume
4,534 shs
Average Volume
27,180 shs
Market Capitalization
$30.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Acasti Pharma MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
85.8% Upside
$6.00 Price Target
Short Interest
Healthy
0.02% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.44) to ($1.29) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.29 out of 5 stars

Medical Sector

309th out of 930 stocks

Pharmaceutical Preparations Industry

133rd out of 423 stocks

ACST stock logo

About Acasti Pharma Stock (NASDAQ:ACST)

Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST Stock Price History

ACST Stock News Headlines

Acasti Pharma Inc Class A
IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
Acasti announces $7.5M private placement equity funding
IRS Loophole Gives Americans An Escape From Inflation
In the years immediately following 2008-09, as the economy stagnated, gold exploded in value. Today, Goldman Sachs is telling its clients that gold may reach $2,250 within the next few years. Don't miss your chance to diversify your savings.
Acasti Pharma: Reverse Stock Split To Become Effective July 10
Acasti Pharma Announces 1-for-6 Reverse Stock Split
Recap: Acasti Pharma Q4 Earnings
Acasti Pharma's Earnings Outlook
H.C. Wainwright Keeps Their Buy Rating on Acasti Pharma (ACST)
See More Headlines
Receive ACST Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Acasti Pharma and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/12/2024
Today
4/17/2024
Next Earnings (Estimated)
6/28/2024
Fiscal Year End
3/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:ACST
Employees
32
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$6.00
High Stock Price Target
$6.00
Low Stock Price Target
$6.00
Potential Upside/Downside
+78.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-42,430,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$9.14 per share

Miscellaneous

Free Float
8,129,000
Market Cap
$31.68 million
Optionable
Not Optionable
Beta
1.49
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Prashant Kohli (Age 52)
    CEO & Director
    Comp: $358.41k
  • Mr. Robert J. DelAversano CPA (Age 52)
    Principal Financial & Accounting Officer
  • Dr. R. Loch MacDonald M.D. (Age 62)
    Ph.D., Member of Scientific Advisory Board & Chief Medical Officer
  • Mr. Amresh Kumar Ph.D. (Age 44)
    VP of Program Management
  • Ms. Carrie D'Andrea (Age 52)
    VP of Clinical Operations

ACST Stock Analysis - Frequently Asked Questions

Should I buy or sell Acasti Pharma stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Acasti Pharma in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACST shares.
View ACST analyst ratings
or view top-rated stocks.

What is Acasti Pharma's stock price target for 2024?

1 equities research analysts have issued 1 year target prices for Acasti Pharma's shares. Their ACST share price targets range from $6.00 to $6.00. On average, they predict the company's share price to reach $6.00 in the next year. This suggests a possible upside of 85.8% from the stock's current price.
View analysts price targets for ACST
or view top-rated stocks among Wall Street analysts.

How have ACST shares performed in 2024?

Acasti Pharma's stock was trading at $2.89 at the start of the year. Since then, ACST shares have increased by 11.8% and is now trading at $3.23.
View the best growth stocks for 2024 here
.

Are investors shorting Acasti Pharma?

Acasti Pharma saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 1,400 shares, a decline of 78.8% from the March 15th total of 6,600 shares. Based on an average daily volume of 29,300 shares, the short-interest ratio is presently 0.0 days. Approximately 0.0% of the company's shares are sold short.
View Acasti Pharma's Short Interest
.

When is Acasti Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, June 28th 2024.
View our ACST earnings forecast
.

How were Acasti Pharma's earnings last quarter?

Acasti Pharma Inc. (NASDAQ:ACST) issued its earnings results on Monday, February, 12th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts' consensus estimates of ($0.23) by $0.02.

When did Acasti Pharma's stock split?

Shares of Acasti Pharma reverse split on Monday, July 10th 2023. The 1-6 reverse split was announced on Monday, July 10th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, July 10th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

What other stocks do shareholders of Acasti Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Acasti Pharma investors own include Matinas BioPharma (MTNB), SCYNEXIS (SCYX), Outlook Therapeutics (OTLK), Bionano Genomics (BNGO), Sorrento Therapeutics (SRNE), ADMA Biologics (ADMA), Heat Biologics (HTBX), KushCo (KSHB), Miragen Therapeutics (MGEN) and Aeterna Zentaris (AEZS).

How do I buy shares of Acasti Pharma?

Shares of ACST stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACST) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners